At the 40 mg dose, 89.1% of participants on zenagamtide reached an A1C below 7% after just 36 weeks — a proportion that demands attention not because it is unprecedented in the GLP-1 class broadly, but because it arrived with 14.6% mean body weight loss from a baseline of roughly 219 lbs, and critically, with no apparent weight-loss plateau in sight at trial’s end. That combination, from a phase 2 dose-finding study in 262 adults with type 2 diabetes, is the clinical argument Novo Nordisk is presenting at ADA 2026 to justify a phase 3 launch in the second half of this year.
The mechanism is the distinctive element. Zenagamtide — also called amycretin — is a unimolecular peptide that co-activates GLP-1 and amylin receptors within a single molecule, distinct from the two-receptor GIP/GLP-1 architecture of tirzepatide. Amylin slows gastric emptying, suppresses postprandial glucagon, and produces satiety signals independent of the GLP-1 pathway, which is precisely why the weight trajectory at higher doses is steep and still descending at week 36. The trial used fixed-dose escalation and permanently discontinued participants who couldn’t tolerate a planned dose — a conservative design choice that means the 14.6% figure reflects a population that cleared every escalation step to 40 mg, not a modified-intent-to-treat average across all randomized patients. Novo Nordisk’s own earlier work with the cagrilintide–semaglutide combination demonstrated that pairing amylin-pathway activity with GLP-1 receptor agonism amplifies weight reduction — zenagamtide compresses that logic into one molecule, which changes manufacturing complexity and potentially adherence dynamics.
The glycemic signal is also unusually clean. From a baseline A1C of 7.8%, the 40 mg arm achieved an estimated mean reduction of 1.71 percentage points against a placebo that drifted only 0.14 points. More striking is the continuous glucose monitoring data: time in range reached 91.5% with the 40 mg dose across all doses exceeding the internationally recommended 70% threshold — and this in participants who had only been on the 40 mg maintenance dose for four weeks. The dose-response was monotonic and statistically significant across all six doses tested. Gastrointestinal adverse events were the most frequent safety signal, described as predominantly mild to moderate, consistent with incretin- and amylin-based therapies as a class.
Novo Nordisk now carries the burden of proving in phase 3 that the tolerability profile holds at scale and that the escalation discontinuation rate doesn’t hollow out the efficacy story in a more heterogeneous population. The one number to track as the phase 3 protocol emerges: the proportion of enrolled patients who successfully reach and sustain the 20 mg and 40 mg maintenance doses, because that completion rate will determine whether the headline weight-loss figures from this phase 2 translate into a real-world label claim or remain a best-case ceiling.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
